{"id":339816,"date":"2025-08-19T18:54:44","date_gmt":"2025-08-19T18:54:44","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-regeneron-pharmaceuticals\/"},"modified":"2025-08-19T18:54:44","modified_gmt":"2025-08-19T18:54:44","slug":"how-to-buy-regeneron-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/","title":{"rendered":"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-339816","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Regeneron Pharmaceuticals (REGN) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Regeneron Pharmaceuticals (REGN) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile \u00f6\u011frenin."},"intro":"Biyoteknolojinin en yenilik\u00e7i \u015firketlerinden birine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Regeneron Pharmaceuticals, t\u0131bbi bilimin \u00f6n saflar\u0131nda yer alarak \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerle hayatlar\u0131 d\u00f6n\u00fc\u015ft\u00fcr\u00fcrken, yat\u0131r\u0131mc\u0131lara y\u00fcksek b\u00fcy\u00fcme potansiyeline sahip biyoteknoloji sekt\u00f6r\u00fcne eri\u015fim sunuyor. Potansiyel blockbuster ila\u00e7larla dolu bir \u00fcr\u00fcn hatt\u0131 ve bilimsel m\u00fckemmeliyet ge\u00e7mi\u015fi ile Regeneron Pharmaceuticals, Inc. (REGN) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 anlamak, t\u0131bb\u0131n gelece\u011fine kat\u0131lman\u0131z i\u00e7in bir kap\u0131 olabilir.","intro_source":{"label":"Intro","type":"text","formatted_value":"Biyoteknolojinin en yenilik\u00e7i \u015firketlerinden birine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Regeneron Pharmaceuticals, t\u0131bbi bilimin \u00f6n saflar\u0131nda yer alarak \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerle hayatlar\u0131 d\u00f6n\u00fc\u015ft\u00fcr\u00fcrken, yat\u0131r\u0131mc\u0131lara y\u00fcksek b\u00fcy\u00fcme potansiyeline sahip biyoteknoloji sekt\u00f6r\u00fcne eri\u015fim sunuyor. Potansiyel blockbuster ila\u00e7larla dolu bir \u00fcr\u00fcn hatt\u0131 ve bilimsel m\u00fckemmeliyet ge\u00e7mi\u015fi ile Regeneron Pharmaceuticals, Inc. (REGN) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 anlamak, t\u0131bb\u0131n gelece\u011fine kat\u0131lman\u0131z i\u00e7in bir kap\u0131 olabilir."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Giri\u015f Noktas\u0131 Analizi<\/h2> <p>19 A\u011fustos 2025 itibar\u0131yla Regeneron Pharmaceuticals (REGN) hisseleri <strong>580,41 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, hisse senedinin ge\u00e7en y\u0131lki dramatik yolculu\u011fu g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6nemli bir f\u0131rsat sunuyor - 52 haftal\u0131k zirvesi olan yakla\u015f\u0131k 1.200 $ seviyesinden yakla\u015f\u0131k %60 d\u00fc\u015f\u00fc\u015f ya\u015fad\u0131, ancak son zamanlarda istikrar ve toparlanma ivmesi g\u00f6steriyor.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131:<\/strong> Ticaret takviminize <strong>29 Ekim 2025<\/strong> tarihini i\u015faretleyin. Bu tarihte Regeneron, 2025 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak ve tarihsel olarak bu t\u00fcr olaylar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur. \u015eirketin 1 A\u011fustos'taki 2. \u00e7eyrek raporu bu deseni m\u00fckemmel \u015fekilde g\u00f6sterdi.<\/p> <h3>Kazan\u00e7lar\u0131n Etkisi Analizi: Haberler REGN Hissesini Nas\u0131l Hareket Ettiriyor<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><th>Analiz<\/th><\/tr> <\/thead> <tbody> <tr><td>1 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td><td>~560 $<\/td><td><strong>%3,6 Art\u0131\u015f<\/strong> (1 hafta)<\/td><td>12,89 $ EPS, 8,43 $ tahminlerini ezdi<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>Itepekimab Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/td><td>~600 $<\/td><td><strong>%19 D\u00fc\u015f\u00fc\u015f<\/strong> (tek g\u00fcn)<\/td><td>KOAH tedavisinde gerileme b\u00fcy\u00fck sat\u0131\u015fa neden oldu<\/td><\/tr> <tr><td>\u015eub 2025<\/td><td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>~520 $<\/td><td><strong>%7,7 Art\u0131\u015f<\/strong><\/td><td>Piyasa zorluklar\u0131na ra\u011fmen sa\u011flam performans<\/td><\/tr> <tr><td>Kas 2024<\/td><td>Dupixent Geni\u015flemesi<\/td><td>~580 $<\/td><td><strong>%4,2 Art\u0131\u015f<\/strong><\/td><td>Yeni endikasyonlar iyimserli\u011fi art\u0131rd\u0131<\/td><\/tr> <tr><td>A\u011fu 2024<\/td><td>T\u00fcm Zamanlar\u0131n En Y\u00fckse\u011fi<\/td><td>1.196 $<\/td><td><strong>%8,3 D\u00fc\u015f\u00fc\u015f<\/strong><\/td><td>Zirve de\u011ferlemeden sonra kar realizasyonu<\/td><\/tr> <tr><td>May\u0131s 2024<\/td><td>EYLEA Rekabeti<\/td><td>~900 $<\/td><td><strong>%12,1 D\u00fc\u015f\u00fc\u015f<\/strong><\/td><td>Pazar pay\u0131 endi\u015feleri ortaya \u00e7\u0131kt\u0131<\/td><\/tr> <\/tbody> <\/table> <p>Desen a\u00e7\u0131k: olumlu klinik deneme sonu\u00e7lar\u0131 veya kazan\u00e7 a\u015f\u0131m\u0131 genellikle %3-8 aras\u0131 kazan\u00e7 sa\u011flarken, olumsuz deneme sonu\u00e7lar\u0131 birka\u00e7 g\u00fcn i\u00e7inde %15-20 d\u00fc\u015f\u00fc\u015fe yol a\u00e7abilir. Bu volatilite stratejik yat\u0131r\u0131mc\u0131lar i\u00e7in hem risk hem de f\u0131rsat yarat\u0131r.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: Krizden Toparlanmaya<\/h2> <p>Regeneron hisseleri \u015eubat 2025'ten beri bir h\u0131z treni yolculu\u011funda:<\/p> <p><strong>\u015eubat 2025:<\/strong> 520 $ (1. \u00e7eyrek kazan\u00e7 sonras\u0131 g\u00fc\u00e7lenme)<br> <strong>Mart 2025:<\/strong> 480 $ (genel piyasa d\u00fczeltmesi)<br> <strong>Nisan 2025:<\/strong> 510 $ (erken toparlanma i\u015faretleri)<br> <strong>May\u0131s 2025:<\/strong> 490 $ (itepekimab deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 \u00e7\u00f6k\u00fc\u015f\u00fc)<br> <strong>Haziran 2025:<\/strong> 530 $ (Dupixent onay\u0131 s\u0131\u00e7ramas\u0131)<br> <strong>Temmuz 2025:<\/strong> 560 $ (istikrarl\u0131 birikim)<br> <strong>A\u011fustos 2025:<\/strong> 580,41 $ (mevcut konsolidasyon)<\/p> <p><strong>%11,6 toparlanma<\/strong> May\u0131s diplerinden dayan\u0131kl\u0131l\u0131\u011f\u0131 g\u00f6steriyor, ancak hisse senedi hala eski parlak g\u00fcnlerinin \u00e7ok alt\u0131nda. Bu, bir\u00e7ok analistin \"de\u011fer bo\u015flu\u011fu\" olarak adland\u0131rd\u0131\u011f\u0131 - mevcut fiyat ile \u00fcr\u00fcn hatt\u0131 potansiyeline dayal\u0131 i\u00e7sel de\u011fer aras\u0131ndaki mesafeyi yarat\u0131yor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve \u00fcr\u00fcn hatt\u0131 geli\u015fmelerine dayanarak, beklenenler:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu:<\/strong> 650-750 $ (y\u00fczde 40-50 y\u00fckseli\u015f potansiyeli) <ul> <li>Kataliz\u00f6rler: 3. \u00e7eyrek kazan\u00e7 a\u015f\u0131m\u0131, ek Dupixent onaylar\u0131<\/li> <li>Risk: Daha fazla klinik deneme gerilemesi<\/li> <\/ul> <\/li> <li><strong>2026 Tahmini:<\/strong> 800-900 $ <ul> <li>\u0130tici G\u00fc\u00e7ler: Lynozyfic pazar penetrasyonu, obezite ilac\u0131 ilerlemesi<\/li> <li>Varsay\u0131m: Stabil d\u00fczenleyici ortam<\/li> <\/ul> <\/li> <li><strong>2028 Projeksiyonu:<\/strong> 1.100-1.300 $ <ul> <li>B\u00fcy\u00fcme: Birden fazla yeni ila\u00e7 onay\u0131, uluslararas\u0131 geni\u015fleme<\/li> <li>Potansiyel: \u00dcr\u00fcn hatt\u0131 adaylar\u0131 i\u00e7in blockbuster stat\u00fcs\u00fc<\/li> <\/ul> <\/li> <li><strong>2030 Vizyonu:<\/strong> 1.500-1.800 $ <ul> <li>D\u00f6n\u00fc\u015f\u00fcm: \u0130mm\u00fcnoloji ve onkolojide hakimiyet<\/li> <li>Belirsizlik: \u00c7\u0131\u011f\u0131r a\u00e7an gen terapisi onaylar\u0131<\/li> <\/ul> <\/li> <\/ul> <p><strong>Karar: UZUN VADEL\u0130 G\u00dc\u00c7L\u00dc ALIM<\/strong> volatiliteyi g\u00f6ze alan yat\u0131r\u0131mc\u0131lar i\u00e7in. Mevcut fiyat, gelecekteki potansiyele g\u00f6re \u00f6nemli bir indirim sunuyor.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <h3>Y\u00fcksek Etkili Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131:<\/strong> May\u0131s 2025 itepekimab felaketi, ge\u00e7 a\u015fama denemelerin bile b\u00fcy\u00fck ba\u015far\u0131s\u0131zl\u0131k ya\u015fayabilece\u011fini ve piyasa de\u011ferinde milyarlarca dolar kayba yol a\u00e7abilece\u011fini g\u00f6sterdi.<\/li> <li><strong>FDA D\u00fczenleyici Engelleri:<\/strong> 2025'teki yeni do\u011frulay\u0131c\u0131 deneme gereksinimleri daha uzun zaman \u00e7izelgeleri ve daha y\u00fcksek maliyetler anlam\u0131na geliyor. Son EYLEA HD \u00f6n dolumlu enjektar reddi, d\u00fczenleyici risklerin yeni ila\u00e7lar\u0131n \u00f6tesine ge\u00e7ti\u011fini g\u00f6steriyor.<\/li> <li><strong>Rekabet Bask\u0131s\u0131:<\/strong> Roche'un Columvi ve Genmab'\u0131n epcoritamab'\u0131 lenfoma tedavilerinde ilerleme kaydediyor, Regeneron'un pazar konumunu tehdit ediyor.<\/li> <li><strong>Patent S\u00fcresi Dolmalar\u0131:<\/strong> \u00d6nemli \u00fcr\u00fcnler sonunda patent u\u00e7urumlar\u0131yla kar\u015f\u0131 kar\u015f\u0131ya, ancak \u00e7o\u011fu 2020'lerin sonlar\u0131na kadar korunuyor.<\/li> <\/ul> <h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3> <ul> <li><strong>Dupixent Hakimiyeti:<\/strong> %22 k\u00fcresel sat\u0131\u015f b\u00fcy\u00fcmesi ile 4,34 milyar $ ve sekiz FDA onay\u0131, bu franchise'\u0131n yava\u015flama belirtisi g\u00f6stermedi\u011fini ortaya koyuyor.<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerlemesi:<\/strong> Lynozyfic multipl miyelom onay\u0131 ve olumlu lenfoma verileri birden fazla gelir ak\u0131\u015f\u0131 yarat\u0131yor.<\/li> <li><strong>Mali G\u00fc\u00e7:<\/strong> 7 milyar $ yat\u0131r\u0131m plan\u0131, son zorluklara ra\u011fmen gelecekteki b\u00fcy\u00fcmeye g\u00fcveni g\u00f6steriyor.<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131:<\/strong> Biyoteknoloji sekt\u00f6r\u00fc 2030'a kadar y\u0131ll\u0131k %8-10 b\u00fcy\u00fcme bekliyor.<\/li> <\/ul> <h2>\ud83d\udcca Stratejik Yat\u0131r\u0131m Tavsiyesi<\/h2> <p>Bug\u00fcn yeni ba\u015flayan yat\u0131r\u0131mc\u0131lar i\u00e7in: <strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n, uzun vadeyi d\u00fc\u015f\u00fcn\u00fcn.<\/strong><\/p> <ol> <li><strong>Ortalama Maliyet Y\u00f6ntemi:<\/strong> Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>D\u00fc\u015f\u00fc\u015fleri Bekleyin:<\/strong> Kazan\u00e7 sonras\u0131 tepkiler genellikle daha iyi giri\u015f noktalar\u0131 yarat\u0131r<\/li> <li><strong>Portf\u00f6y Da\u011f\u0131l\u0131m\u0131:<\/strong> Volatilite nedeniyle REGN'yi toplam portf\u00f6y\u00fcn %5-10'u ile s\u0131n\u0131rlay\u0131n<\/li> <li><strong>Uyar\u0131lar Kurun:<\/strong> Klinik deneme duyurular\u0131n\u0131 ve FDA kararlar\u0131n\u0131 takip edin<\/li> <\/ol> <p>Mizahi deneyimli tavsiye: \"REGN ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir - inan\u0131lmaz \u00f6d\u00fcllendirici ama beklenmedik patlamalara meyillidir. G\u00fcvenlik g\u00f6zl\u00fcklerinizi tak\u0131n ve pozisyon b\u00fcy\u00fckl\u00fcklerinizi makul tutun!\"<\/p> <h2>\u2705 Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>D\u00fczenleyici uyumluluk i\u00e7in kimlik belgeleri sa\u011flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>Fon Yat\u0131r\u0131n<\/td><td>Risk alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>G\u00fcncel Fiyat\u0131 Ara\u015ft\u0131r\u0131n<\/td><td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 580,41 $ (19 A\u011fu itibar\u0131yla) kontrol edin<\/td><\/tr> <tr><td>5<\/td><td>Limit Emirleri Kullan\u0131n<\/td><td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131 belirleyin<\/td><\/tr> <tr><td>6<\/td><td>Pozisyonu \u0130zleyin<\/td><td>Performans\u0131 takip edin ve zarar durdurma emirleri koyun<\/td><\/tr> <tr><td>7<\/td><td>Temett\u00fcleri Yeniden Yat\u0131r\u0131n<\/td><td>REGN \u00fc\u00e7 ayda bir 3,52 $ (y\u00fczde 0,61 getiri) \u00f6der<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Cazip?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, REGN'nin \u00f6zellikleriyle m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Yat\u0131r\u0131m:<\/strong> Sadece 5 $ ile stratejileri d\u00fc\u015f\u00fck riskle test edebilirsiniz<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama:<\/strong> Tek belge KYC s\u00fcreci sayesinde dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flayabilirsiniz<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri:<\/strong> Kripto paralar ve e-c\u00fczdanlar dahil 100'den fazla y\u00f6ntem<\/li> <li><strong>E\u011fitim Kaynaklar\u0131:<\/strong> <a href=\"\/blog\">Pocket Option blogu<\/a> s\u00fcrekli piyasa i\u00e7g\u00f6r\u00fcleri sa\u011flar<\/li> <\/ul> <p>Bu eri\u015filebilirlik, b\u00fcy\u00fck sermaye taahh\u00fct etmeden REGN gibi y\u00fcksek potansiyelli hisselere maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option'u ideal k\u0131lar.<\/p> <h2>\ud83c\udfe2 \u015eirket Genel Bak\u0131\u015f\u0131: 2025'te Regeneron<\/h2> <p>Regeneron Pharmaceuticals, y\u0131ll\u0131k 14,2 milyar $ gelir ve d\u00fcnya \u00e7ap\u0131nda 15.000'den fazla \u00e7al\u0131\u015fan\u0131yla biyoteknoloji devi olarak \u00f6ne \u00e7\u0131k\u0131yor. \u015eirketin misyonu, imm\u00fcnoloji, onkoloji, oftalmoloji ve nadir hastal\u0131klar dahil olmak \u00fczere bir\u00e7ok terap\u00f6tik alanda d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc ila\u00e7lar geli\u015ftirmek i\u00e7in son teknoloji bilimi kullanmakt\u0131r.<\/p> <p>1988'de doktor-bilim insanlar\u0131 taraf\u0131ndan kurulan Regeneron, bilimsel b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc koruyarak ticari bir dev haline geldi. \u00d6zel VelociSuite teknolojileri, yakla\u015f\u0131k 45 \u00fcr\u00fcn\u00fcn klinik geli\u015ftirme a\u015famas\u0131nda oldu\u011fu bir\u00e7ok \u00e7\u0131\u011f\u0131r a\u00e7an tedavi \u00fcretti.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Regeneron'un genel merkezi, \u00e7al\u0131\u015fanlar\u0131n her kat\u0131n hangi imza kokusunu yayaca\u011f\u0131na haftal\u0131k oy verdi\u011fi parf\u00fcm da\u011f\u0131tan asans\u00f6rlere sahip - yenilik\u00e7i ruhlar\u0131n\u0131 yans\u0131tan benzersiz bir kurumsal k\u00fclt\u00fcr yakla\u015f\u0131m\u0131!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Giri\u015f Noktas\u0131 Analizi<\/h2>\n<p>19 A\u011fustos 2025 itibar\u0131yla Regeneron Pharmaceuticals (REGN) hisseleri <strong>580,41 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, hisse senedinin ge\u00e7en y\u0131lki dramatik yolculu\u011fu g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6nemli bir f\u0131rsat sunuyor &#8211; 52 haftal\u0131k zirvesi olan yakla\u015f\u0131k 1.200 $ seviyesinden yakla\u015f\u0131k %60 d\u00fc\u015f\u00fc\u015f ya\u015fad\u0131, ancak son zamanlarda istikrar ve toparlanma ivmesi g\u00f6steriyor.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131:<\/strong> Ticaret takviminize <strong>29 Ekim 2025<\/strong> tarihini i\u015faretleyin. Bu tarihte Regeneron, 2025 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak ve tarihsel olarak bu t\u00fcr olaylar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur. \u015eirketin 1 A\u011fustos&#8217;taki 2. \u00e7eyrek raporu bu deseni m\u00fckemmel \u015fekilde g\u00f6sterdi.<\/p>\n<h3>Kazan\u00e7lar\u0131n Etkisi Analizi: Haberler REGN Hissesini Nas\u0131l Hareket Ettiriyor<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<th>Analiz<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td>\n<td>~560 $<\/td>\n<td><strong>%3,6 Art\u0131\u015f<\/strong> (1 hafta)<\/td>\n<td>12,89 $ EPS, 8,43 $ tahminlerini ezdi<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>Itepekimab Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/td>\n<td>~600 $<\/td>\n<td><strong>%19 D\u00fc\u015f\u00fc\u015f<\/strong> (tek g\u00fcn)<\/td>\n<td>KOAH tedavisinde gerileme b\u00fcy\u00fck sat\u0131\u015fa neden oldu<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>~520 $<\/td>\n<td><strong>%7,7 Art\u0131\u015f<\/strong><\/td>\n<td>Piyasa zorluklar\u0131na ra\u011fmen sa\u011flam performans<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>Dupixent Geni\u015flemesi<\/td>\n<td>~580 $<\/td>\n<td><strong>%4,2 Art\u0131\u015f<\/strong><\/td>\n<td>Yeni endikasyonlar iyimserli\u011fi art\u0131rd\u0131<\/td>\n<\/tr>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>T\u00fcm Zamanlar\u0131n En Y\u00fckse\u011fi<\/td>\n<td>1.196 $<\/td>\n<td><strong>%8,3 D\u00fc\u015f\u00fc\u015f<\/strong><\/td>\n<td>Zirve de\u011ferlemeden sonra kar realizasyonu<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2024<\/td>\n<td>EYLEA Rekabeti<\/td>\n<td>~900 $<\/td>\n<td><strong>%12,1 D\u00fc\u015f\u00fc\u015f<\/strong><\/td>\n<td>Pazar pay\u0131 endi\u015feleri ortaya \u00e7\u0131kt\u0131<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Desen a\u00e7\u0131k: olumlu klinik deneme sonu\u00e7lar\u0131 veya kazan\u00e7 a\u015f\u0131m\u0131 genellikle %3-8 aras\u0131 kazan\u00e7 sa\u011flarken, olumsuz deneme sonu\u00e7lar\u0131 birka\u00e7 g\u00fcn i\u00e7inde %15-20 d\u00fc\u015f\u00fc\u015fe yol a\u00e7abilir. Bu volatilite stratejik yat\u0131r\u0131mc\u0131lar i\u00e7in hem risk hem de f\u0131rsat yarat\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: Krizden Toparlanmaya<\/h2>\n<p>Regeneron hisseleri \u015eubat 2025&#8217;ten beri bir h\u0131z treni yolculu\u011funda:<\/p>\n<p><strong>\u015eubat 2025:<\/strong> 520 $ (1. \u00e7eyrek kazan\u00e7 sonras\u0131 g\u00fc\u00e7lenme)<br \/> <strong>Mart 2025:<\/strong> 480 $ (genel piyasa d\u00fczeltmesi)<br \/> <strong>Nisan 2025:<\/strong> 510 $ (erken toparlanma i\u015faretleri)<br \/> <strong>May\u0131s 2025:<\/strong> 490 $ (itepekimab deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 \u00e7\u00f6k\u00fc\u015f\u00fc)<br \/> <strong>Haziran 2025:<\/strong> 530 $ (Dupixent onay\u0131 s\u0131\u00e7ramas\u0131)<br \/> <strong>Temmuz 2025:<\/strong> 560 $ (istikrarl\u0131 birikim)<br \/> <strong>A\u011fustos 2025:<\/strong> 580,41 $ (mevcut konsolidasyon)<\/p>\n<p><strong>%11,6 toparlanma<\/strong> May\u0131s diplerinden dayan\u0131kl\u0131l\u0131\u011f\u0131 g\u00f6steriyor, ancak hisse senedi hala eski parlak g\u00fcnlerinin \u00e7ok alt\u0131nda. Bu, bir\u00e7ok analistin &#8220;de\u011fer bo\u015flu\u011fu&#8221; olarak adland\u0131rd\u0131\u011f\u0131 &#8211; mevcut fiyat ile \u00fcr\u00fcn hatt\u0131 potansiyeline dayal\u0131 i\u00e7sel de\u011fer aras\u0131ndaki mesafeyi yarat\u0131yor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve \u00fcr\u00fcn hatt\u0131 geli\u015fmelerine dayanarak, beklenenler:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu:<\/strong> 650-750 $ (y\u00fczde 40-50 y\u00fckseli\u015f potansiyeli)\n<ul>\n<li>Kataliz\u00f6rler: 3. \u00e7eyrek kazan\u00e7 a\u015f\u0131m\u0131, ek Dupixent onaylar\u0131<\/li>\n<li>Risk: Daha fazla klinik deneme gerilemesi<\/li>\n<\/ul>\n<\/li>\n<li><strong>2026 Tahmini:<\/strong> 800-900 $\n<ul>\n<li>\u0130tici G\u00fc\u00e7ler: Lynozyfic pazar penetrasyonu, obezite ilac\u0131 ilerlemesi<\/li>\n<li>Varsay\u0131m: Stabil d\u00fczenleyici ortam<\/li>\n<\/ul>\n<\/li>\n<li><strong>2028 Projeksiyonu:<\/strong> 1.100-1.300 $\n<ul>\n<li>B\u00fcy\u00fcme: Birden fazla yeni ila\u00e7 onay\u0131, uluslararas\u0131 geni\u015fleme<\/li>\n<li>Potansiyel: \u00dcr\u00fcn hatt\u0131 adaylar\u0131 i\u00e7in blockbuster stat\u00fcs\u00fc<\/li>\n<\/ul>\n<\/li>\n<li><strong>2030 Vizyonu:<\/strong> 1.500-1.800 $\n<ul>\n<li>D\u00f6n\u00fc\u015f\u00fcm: \u0130mm\u00fcnoloji ve onkolojide hakimiyet<\/li>\n<li>Belirsizlik: \u00c7\u0131\u011f\u0131r a\u00e7an gen terapisi onaylar\u0131<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Karar: UZUN VADEL\u0130 G\u00dc\u00c7L\u00dc ALIM<\/strong> volatiliteyi g\u00f6ze alan yat\u0131r\u0131mc\u0131lar i\u00e7in. Mevcut fiyat, gelecekteki potansiyele g\u00f6re \u00f6nemli bir indirim sunuyor.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<h3>Y\u00fcksek Etkili Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131:<\/strong> May\u0131s 2025 itepekimab felaketi, ge\u00e7 a\u015fama denemelerin bile b\u00fcy\u00fck ba\u015far\u0131s\u0131zl\u0131k ya\u015fayabilece\u011fini ve piyasa de\u011ferinde milyarlarca dolar kayba yol a\u00e7abilece\u011fini g\u00f6sterdi.<\/li>\n<li><strong>FDA D\u00fczenleyici Engelleri:<\/strong> 2025&#8217;teki yeni do\u011frulay\u0131c\u0131 deneme gereksinimleri daha uzun zaman \u00e7izelgeleri ve daha y\u00fcksek maliyetler anlam\u0131na geliyor. Son EYLEA HD \u00f6n dolumlu enjektar reddi, d\u00fczenleyici risklerin yeni ila\u00e7lar\u0131n \u00f6tesine ge\u00e7ti\u011fini g\u00f6steriyor.<\/li>\n<li><strong>Rekabet Bask\u0131s\u0131:<\/strong> Roche&#8217;un Columvi ve Genmab&#8217;\u0131n epcoritamab&#8217;\u0131 lenfoma tedavilerinde ilerleme kaydediyor, Regeneron&#8217;un pazar konumunu tehdit ediyor.<\/li>\n<li><strong>Patent S\u00fcresi Dolmalar\u0131:<\/strong> \u00d6nemli \u00fcr\u00fcnler sonunda patent u\u00e7urumlar\u0131yla kar\u015f\u0131 kar\u015f\u0131ya, ancak \u00e7o\u011fu 2020&#8217;lerin sonlar\u0131na kadar korunuyor.<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3>\n<ul>\n<li><strong>Dupixent Hakimiyeti:<\/strong> %22 k\u00fcresel sat\u0131\u015f b\u00fcy\u00fcmesi ile 4,34 milyar $ ve sekiz FDA onay\u0131, bu franchise&#8217;\u0131n yava\u015flama belirtisi g\u00f6stermedi\u011fini ortaya koyuyor.<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerlemesi:<\/strong> Lynozyfic multipl miyelom onay\u0131 ve olumlu lenfoma verileri birden fazla gelir ak\u0131\u015f\u0131 yarat\u0131yor.<\/li>\n<li><strong>Mali G\u00fc\u00e7:<\/strong> 7 milyar $ yat\u0131r\u0131m plan\u0131, son zorluklara ra\u011fmen gelecekteki b\u00fcy\u00fcmeye g\u00fcveni g\u00f6steriyor.<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131:<\/strong> Biyoteknoloji sekt\u00f6r\u00fc 2030&#8217;a kadar y\u0131ll\u0131k %8-10 b\u00fcy\u00fcme bekliyor.<\/li>\n<\/ul>\n<h2>\ud83d\udcca Stratejik Yat\u0131r\u0131m Tavsiyesi<\/h2>\n<p>Bug\u00fcn yeni ba\u015flayan yat\u0131r\u0131mc\u0131lar i\u00e7in: <strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n, uzun vadeyi d\u00fc\u015f\u00fcn\u00fcn.<\/strong><\/p>\n<ol>\n<li><strong>Ortalama Maliyet Y\u00f6ntemi:<\/strong> Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>D\u00fc\u015f\u00fc\u015fleri Bekleyin:<\/strong> Kazan\u00e7 sonras\u0131 tepkiler genellikle daha iyi giri\u015f noktalar\u0131 yarat\u0131r<\/li>\n<li><strong>Portf\u00f6y Da\u011f\u0131l\u0131m\u0131:<\/strong> Volatilite nedeniyle REGN&#8217;yi toplam portf\u00f6y\u00fcn %5-10&#8217;u ile s\u0131n\u0131rlay\u0131n<\/li>\n<li><strong>Uyar\u0131lar Kurun:<\/strong> Klinik deneme duyurular\u0131n\u0131 ve FDA kararlar\u0131n\u0131 takip edin<\/li>\n<\/ol>\n<p>Mizahi deneyimli tavsiye: &#8220;REGN ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir &#8211; inan\u0131lmaz \u00f6d\u00fcllendirici ama beklenmedik patlamalara meyillidir. G\u00fcvenlik g\u00f6zl\u00fcklerinizi tak\u0131n ve pozisyon b\u00fcy\u00fckl\u00fcklerinizi makul tutun!&#8221;<\/p>\n<h2>\u2705 Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>D\u00fczenleyici uyumluluk i\u00e7in kimlik belgeleri sa\u011flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon Yat\u0131r\u0131n<\/td>\n<td>Risk alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>G\u00fcncel Fiyat\u0131 Ara\u015ft\u0131r\u0131n<\/td>\n<td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 580,41 $ (19 A\u011fu itibar\u0131yla) kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limit Emirleri Kullan\u0131n<\/td>\n<td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonu \u0130zleyin<\/td>\n<td>Performans\u0131 takip edin ve zarar durdurma emirleri koyun<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Temett\u00fcleri Yeniden Yat\u0131r\u0131n<\/td>\n<td>REGN \u00fc\u00e7 ayda bir 3,52 $ (y\u00fczde 0,61 getiri) \u00f6der<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Cazip?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, REGN&#8217;nin \u00f6zellikleriyle m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Yat\u0131r\u0131m:<\/strong> Sadece 5 $ ile stratejileri d\u00fc\u015f\u00fck riskle test edebilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama:<\/strong> Tek belge KYC s\u00fcreci sayesinde dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri:<\/strong> Kripto paralar ve e-c\u00fczdanlar dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131:<\/strong> <a href=\"\/blog\">Pocket Option blogu<\/a> s\u00fcrekli piyasa i\u00e7g\u00f6r\u00fcleri sa\u011flar<\/li>\n<\/ul>\n<p>Bu eri\u015filebilirlik, b\u00fcy\u00fck sermaye taahh\u00fct etmeden REGN gibi y\u00fcksek potansiyelli hisselere maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option&#8217;u ideal k\u0131lar.<\/p>\n<h2>\ud83c\udfe2 \u015eirket Genel Bak\u0131\u015f\u0131: 2025&#8217;te Regeneron<\/h2>\n<p>Regeneron Pharmaceuticals, y\u0131ll\u0131k 14,2 milyar $ gelir ve d\u00fcnya \u00e7ap\u0131nda 15.000&#8217;den fazla \u00e7al\u0131\u015fan\u0131yla biyoteknoloji devi olarak \u00f6ne \u00e7\u0131k\u0131yor. \u015eirketin misyonu, imm\u00fcnoloji, onkoloji, oftalmoloji ve nadir hastal\u0131klar dahil olmak \u00fczere bir\u00e7ok terap\u00f6tik alanda d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc ila\u00e7lar geli\u015ftirmek i\u00e7in son teknoloji bilimi kullanmakt\u0131r.<\/p>\n<p>1988&#8217;de doktor-bilim insanlar\u0131 taraf\u0131ndan kurulan Regeneron, bilimsel b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc koruyarak ticari bir dev haline geldi. \u00d6zel VelociSuite teknolojileri, yakla\u015f\u0131k 45 \u00fcr\u00fcn\u00fcn klinik geli\u015ftirme a\u015famas\u0131nda oldu\u011fu bir\u00e7ok \u00e7\u0131\u011f\u0131r a\u00e7an tedavi \u00fcretti.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Regeneron&#8217;un genel merkezi, \u00e7al\u0131\u015fanlar\u0131n her kat\u0131n hangi imza kokusunu yayaca\u011f\u0131na haftal\u0131k oy verdi\u011fi parf\u00fcm da\u011f\u0131tan asans\u00f6rlere sahip &#8211; yenilik\u00e7i ruhlar\u0131n\u0131 yans\u0131tan benzersiz bir kurumsal k\u00fclt\u00fcr yakla\u015f\u0131m\u0131!<\/p>\n"},"faq":[{"question":"Regeneron Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, g\u00fcncel fiyat\u0131 kontrol edin, limit emirleri kullanarak hisse sat\u0131n al\u0131n ve pozisyonunuzu izleyin."},{"question":"Regeneron hisseleri i\u00e7in riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA d\u00fczenleyici engelleri, rekabet bask\u0131s\u0131 ve patent s\u00fcresi dolmalar\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Regeneron'un 2025 sonras\u0131 fiyat beklentisi nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 650-750 $, 2030'da ise 1.500-1.800 $ aras\u0131nda fiyatlar beklenmektedir."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum yat\u0131r\u0131m, h\u0131zl\u0131 do\u011frulama, \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ve e\u011fitim kaynaklar\u0131 sunmas\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir."},{"question":"Regeneron'un g\u00fc\u00e7l\u00fc y\u00f6nleri nelerdir?","answer":"G\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131, Dupixent'in pazar hakimiyeti, finansal g\u00fc\u00e7 ve biyoteknoloji sekt\u00f6r\u00fcndeki b\u00fcy\u00fcme potansiyeli g\u00fc\u00e7l\u00fc y\u00f6nleridir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Regeneron Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, g\u00fcncel fiyat\u0131 kontrol edin, limit emirleri kullanarak hisse sat\u0131n al\u0131n ve pozisyonunuzu izleyin."},{"question":"Regeneron hisseleri i\u00e7in riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA d\u00fczenleyici engelleri, rekabet bask\u0131s\u0131 ve patent s\u00fcresi dolmalar\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Regeneron'un 2025 sonras\u0131 fiyat beklentisi nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 650-750 $, 2030'da ise 1.500-1.800 $ aras\u0131nda fiyatlar beklenmektedir."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum yat\u0131r\u0131m, h\u0131zl\u0131 do\u011frulama, \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ve e\u011fitim kaynaklar\u0131 sunmas\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir."},{"question":"Regeneron'un g\u00fc\u00e7l\u00fc y\u00f6nleri nelerdir?","answer":"G\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131, Dupixent'in pazar hakimiyeti, finansal g\u00fc\u00e7 ve biyoteknoloji sekt\u00f6r\u00fcndeki b\u00fcy\u00fcme potansiyeli g\u00fc\u00e7l\u00fc y\u00f6nleridir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T18:54:44+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-19T18:54:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/\",\"name\":\"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"datePublished\":\"2025-08-19T18:54:44+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T18:54:44+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-19T18:54:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/","name":"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","datePublished":"2025-08-19T18:54:44+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Regeneron Pharmaceuticals, Inc. (REGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Regeneron Pharmaceuticals, Inc. (REGN) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":339819,"slug":"how-to-buy-regeneron-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Regeneron Pharmaceuticals, Inc. (REGN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Regeneron Pharmaceuticals, Inc. (REGN)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":339822,"slug":"how-to-buy-regeneron-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Regeneron Pharmaceuticals, Inc. (REGN) - Investimento em a\u00e7\u00f5es da Regeneron Pharmaceuticals, Inc. (REGN)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-regeneron-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/339816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=339816"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/339816\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334063"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=339816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=339816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=339816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}